Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Database Analysis Finds IMRT More Effective Than CRT and Proton Beam in Prostate Cancer

March 29th 2012

IMRT was superior to CRT in reducing recurrence and significant side effects in men with localized prostate cancer, according to a comparative effectiveness study based on the SEER-Medicare database.

PSA Testing Linked to Reduced Mortality

March 15th 2012

PSA testing was shown to significantly reduce mortality among men, but the test had no effect on all-cause mortality.

Consensus Elusive on Standard for Lowering Testosterone Levels

March 12th 2012

Once injectable agents were proven to lower testosterone levels, they became the preferred treatment among patients and their treatment teams.

Zytiga Study Unblinded Following Positive Interim Analysis

March 9th 2012

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

No Increased Risk of Cardiovascular Death With Androgen Deprivation Therapy for Prostate Cancer

March 7th 2012

A meta-analysis shows no apparent association between androgen deprivation therapy and cardiovascular events and death in men with prostate cancer.

Dr. Gomella on the Cost of the Immunotherapy Sipuleucel-T

March 1st 2012

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on the Cost of the Immunotherapy Sipuleucel-T

Predicting Prostate Outcomes: Nomograms Help Patients Sort Options, But Caution Is Urged

February 29th 2012

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

Yearly Prostate Cancer Screening Does Not Provide Mortality Benefit

February 28th 2012

Annual prostate cancer screening does not decrease mortality from prostate cancer more than opportunistic screening.

Dr. Petrylak Discusses the Isotope Radium-223

February 28th 2012

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Isotope Radium-223

IPCC Conference to Focus on Issues Facing Clinicians

February 22nd 2012

In March, a one-day conference will provide specialists with practical information they need to provide their patients with the best in diagnostic and therapeutic care.

Dr. Gomella Discusses the NeoACT Sipuleucel-T Study

February 15th 2012

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses the NeoACT Sipuleucel-T Study

Radiation Added to Hormone Therapy Bests Hormone Therapy Alone for High-Risk Prostate Cancer

February 9th 2012

Radiation therapy added to androgen deprivation therapy prolongs overall survival in men with locally advanced or otherwise high-risk prostate cancer.

FDA Updates: Pertuzumab Moves Forward, Denosumab Receives Setback

February 8th 2012

While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

The Prostate Cancer Microenvironment: Implications for Therapy

February 6th 2012

In order to design new treatments for prostate cancer and prolong the lives of patients with the disease, researchers are going to have to delve into the tumor microenvironment.

Lenalidomide Plus Docetaxel: Phase III Results Fall Short

February 3rd 2012

The combination of lenalidomide and docetaxel for treatment of CRPC failed to produce results in the large phase III MAINSAIL trial.

Prostate Cancer Armamentarium Expanding

January 20th 2012

Men with prostate cancer now have an array of treatments, which was not the case a decade ago.

Benefit of ADT Added to Radiation Confined to Intermediate- Risk Prostate Cancer Patients With Poor Prognosis

January 19th 2012

Not all intermediate-risk prostate cancer patients benefit from the addition of androgen deprivation therapy to radiation therapy.

Tasquinimod Shows Potential for Metastatic Castration-Resistant Prostate Cancer

January 17th 2012

The investigational compound tasquinimod significantly postpones disease progression and increases PFS in men with minimally symptomatic, metastatic CRPC.

DNA Analysis Finds First Gene Implicated in Prostate Cancer

January 12th 2012

A statistical analysis led to the discovery of the first high-risk genetic mutation associated with hereditary prostate cancer.

Dr. Logothetis Discusses Prostate Cancer Therapy

January 11th 2012

Dr. Christopher Logothetis, from the MD Anderson Cancer Center, Discusses Prostate Cancer Therapy